

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



PuraPharm

PURAPHARM CORPORATION LIMITED

培力農本方有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1498)

TERMINATION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE

Placing Agent

華通證券國際

— Waton Securities International Limited —

Waton Securities International Limited

Reference is made to the announcement of the Company dated 28 March 2024 in relation to the Placing (the “**Announcement**”) and the supplemental announcement in relation to the Placing dated 5 April 2024. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the **Announcement**.

Termination of Placing Agreement

The Board announces that on 12 April 2024 (after trading hours), the Placing Agent served a written notice of termination to terminate the Placing Agreement pursuant to the terms thereof. Upon termination of the Placing Agreement, all liabilities of the parties to the Placing Agreement shall cease and determine and no party thereto shall have any claim against the other party in respect of any matter or thing arising out of or in connection with the Placing Agreement save in respect of any antecedent breach of any obligation under the Placing Agreement.

The Directors are of the view that the termination of the Placing Agreement and the Placing contemplated thereunder has no material adverse impact on the business operations and financial position of the Group. The Company may consider engaging in further fund raising activities after taking into account the future development of the Group and the market conditions. Further announcement(s) will be made by the Company as and when any disclosure requirement is triggered by the materialisation of any such fund raising opportunities.

By order of the Board
PuraPharm Corporation Limited
Chan Yu Ling, Abraham
Chairman and Executive Director

Hong Kong, 12 April 2024

As at the date of this announcement, the executive Directors of the Company are Mr. Chan Yu Ling, Abraham and Ms. Man Yee Wai, Viola; the non-executive Director of the Company is Mr. Leung Stephen Kwok Keung; and the independent non-executive Directors of the Company are Mr. Ho Kwok Wah, George, Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.